Multiple Sclerosis 2 - Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Novartis denies physicians’ reports of Mayzent launch delays

Multiple Sclerosis 2
Reports of the delays come from two neurologists who spoke on the sidelines of the American Academy of Neurology annual meeting in Philadelphia, Pennsylvania.